[8-K] ARS Pharmaceuticals, Inc. Reports Material Event
ARS Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2025 via a press release attached to this Form 8-K as Exhibit 99.1. The company states that the press release is furnished and expressly not "filed" for purposes of the Exchange Act, and therefore is not incorporated by reference into other filings. The filing also confirms that ARS is an emerging growth company and that its common stock trades on The Nasdaq Stock Market under the symbol SPRY.
The company also updated its corporate investor presentation, which is available on the company website and is attached as Exhibit 99.2. The 8-K repeats that the presentation is furnished and not deemed filed, and lists the exhibits including the Interactive Data File Cover Page as Exhibit 104.
ARS Pharmaceuticals, Inc. ha comunicato i risultati finanziari per il trimestre terminato 30 giugno 2025 tramite un comunicato stampa allegato al presente Form 8-K come Exhibit 99.1. La società precisa che il comunicato è furnished e espressamente non 'filed' ai fini della Exchange Act, pertanto non viene incorporato per riferimento in altri documenti. Il deposito conferma inoltre che ARS è una emerging growth company e che le azioni ordinarie sono quotate al Nasdaq con il simbolo SPRY.
La società ha aggiornato anche la presentazione per gli investitori aziendali, disponibile sul sito web e allegata come Exhibit 99.2. L'8-K ribadisce che la presentazione è furnished e non è considerata 'filed', e indica gli allegati inclusa la Cover Page del file di dati interattivi come Exhibit 104.
ARS Pharmaceuticals, Inc. anunció sus resultados financieros correspondientes al trimestre terminado el 30 de junio de 2025 mediante un comunicado de prensa adjunto a este Form 8-K como Exhibit 99.1. La compañía señala que el comunicado está furnished y expresamente no es 'filed' a efectos de la Exchange Act, por lo que no se incorpora por referencia en otros registros. El formulario también confirma que ARS es una emerging growth company y que sus acciones ordinarias cotizan en The Nasdaq Stock Market con el símbolo SPRY.
Además, la empresa actualizó su presentación corporativa para inversores, disponible en su sitio web y adjunta como Exhibit 99.2. El 8-K reitera que la presentación está furnished y no se considera 'filed', y enumera los anexos, incluida la Cover Page del archivo de datos interactivos como Exhibit 104.
ARS Pharmaceuticals, Inc.는 2025년 6월 30일로 종료된 분기의 재무 실적을 본 Form 8-K에 첨부된 보도자료(Exhibit 99.1)를 통해 발표했습니다. 회사는 해당 보도자료가 furnished이며 명시적으로 'filed'가 아니라고 밝혔고, 따라서 다른 제출서류에 참조로 통합되지 않는다고 명시했습니다. 제출서류는 또한 ARS가 emerging growth company임을 확인하며 보통주가 Nasdaq에서 SPRY라는 심볼로 거래되고 있음을 명시합니다.
회사는 기업 투자자용 프레젠테이션도 업데이트했으며, 이는 회사 웹사이트에서 확인할 수 있고 Exhibit 99.2로 첨부되어 있습니다. 8-K는 프레젠테이션 역시 furnished로 제공되었으며 'filed'로 간주되지 않는다고 반복하고, 인터랙티브 데이터 파일의 Cover Page를 Exhibit 104로 포함한 부속 문서를 열거합니다.
ARS Pharmaceuticals, Inc. a annoncé ses résultats financiers pour le trimestre clos le 30 juin 2025 par un communiqué de presse joint à ce Form 8-K en tant que Exhibit 99.1. La société indique que le communiqué est furnished et expressément non 'filed' aux fins de la Exchange Act, et n'est donc pas incorporé par référence dans d'autres dépôts. Le dépôt confirme également qu'ARS est une emerging growth company et que ses actions ordinaires sont négociées sur le Nasdaq sous le symbole SPRY.
La société a également mis à jour sa présentation aux investisseurs, disponible sur son site web et jointe en tant que Exhibit 99.2. Le Form 8-K répète que la présentation est furnished et n'est pas réputée 'filed', et énumère les annexes, y compris la Cover Page du fichier de données interactives en tant qu'Exhibit 104.
ARS Pharmaceuticals, Inc. gab die Finanzergebnisse für das Quartal zum 30. Juni 2025 in einer Pressemitteilung bekannt, die diesem Form 8-K als Exhibit 99.1 beigefügt ist. Das Unternehmen erklärt, dass die Pressemitteilung furnished und ausdrücklich nicht 'filed' im Sinne des Exchange Act ist und daher nicht durch Verweis in andere Einreichungen aufgenommen wird. Die Einreichung bestätigt zudem, dass ARS eine emerging growth company ist und dass die Stammaktien an der Nasdaq unter dem Symbol SPRY gehandelt werden.
Das Unternehmen hat außerdem seine Investorenpräsentation aktualisiert, die auf der Unternehmenswebsite verfügbar ist und als Exhibit 99.2 beigefügt wurde. Das 8-K wiederholt, dass die Präsentation furnished und nicht als 'filed' anzusehen ist, und listet die Anlagen auf, darunter die Cover Page der Interactive Data File als Exhibit 104.
- Press release announcing Q2 results attached as Exhibit 99.1, making the company's quarterly disclosure available to investors
- Updated investor presentation attached as Exhibit 99.2 and posted on the company website
- Clear legal treatment noted: exhibits are furnished and not deemed filed, clarifying incorporation status
- Company trades as SPRY on The Nasdaq Stock Market; the filing reiterates the ticker and exchange
- None.
Insights
TL;DR: Routine 8-K furnishing quarterly results and an updated investor deck; no financial details are presented here.
The filing notifies investors that ARS furnished a press release with Q2 results (quarter ended June 30, 2025) and an updated corporate presentation, both attached as Exhibits 99.1 and 99.2. Because the company explicitly states these items are "furnished" and not "filed," the disclosures carry the narrower legal treatment typical of routine operational updates. The 8-K provides no earnings, revenue, or cash-flow figures, so material financial analysis cannot be performed from this filing alone.
TL;DR: Governance disclosure is standard: furnished materials and investor presentation posted; no governance changes disclosed.
The report confirms availability of investor-facing materials and reiterates the legal status of those materials as furnished rather than filed, limiting incorporation by reference. There is no mention of officer changes, board actions, securities issuances, or other governance events. For governance or material-event monitoring, stakeholders must review the attached exhibits themselves since substantive data are not included in the 8-K text.
ARS Pharmaceuticals, Inc. ha comunicato i risultati finanziari per il trimestre terminato 30 giugno 2025 tramite un comunicato stampa allegato al presente Form 8-K come Exhibit 99.1. La società precisa che il comunicato è furnished e espressamente non 'filed' ai fini della Exchange Act, pertanto non viene incorporato per riferimento in altri documenti. Il deposito conferma inoltre che ARS è una emerging growth company e che le azioni ordinarie sono quotate al Nasdaq con il simbolo SPRY.
La società ha aggiornato anche la presentazione per gli investitori aziendali, disponibile sul sito web e allegata come Exhibit 99.2. L'8-K ribadisce che la presentazione è furnished e non è considerata 'filed', e indica gli allegati inclusa la Cover Page del file di dati interattivi come Exhibit 104.
ARS Pharmaceuticals, Inc. anunció sus resultados financieros correspondientes al trimestre terminado el 30 de junio de 2025 mediante un comunicado de prensa adjunto a este Form 8-K como Exhibit 99.1. La compañía señala que el comunicado está furnished y expresamente no es 'filed' a efectos de la Exchange Act, por lo que no se incorpora por referencia en otros registros. El formulario también confirma que ARS es una emerging growth company y que sus acciones ordinarias cotizan en The Nasdaq Stock Market con el símbolo SPRY.
Además, la empresa actualizó su presentación corporativa para inversores, disponible en su sitio web y adjunta como Exhibit 99.2. El 8-K reitera que la presentación está furnished y no se considera 'filed', y enumera los anexos, incluida la Cover Page del archivo de datos interactivos como Exhibit 104.
ARS Pharmaceuticals, Inc.는 2025년 6월 30일로 종료된 분기의 재무 실적을 본 Form 8-K에 첨부된 보도자료(Exhibit 99.1)를 통해 발표했습니다. 회사는 해당 보도자료가 furnished이며 명시적으로 'filed'가 아니라고 밝혔고, 따라서 다른 제출서류에 참조로 통합되지 않는다고 명시했습니다. 제출서류는 또한 ARS가 emerging growth company임을 확인하며 보통주가 Nasdaq에서 SPRY라는 심볼로 거래되고 있음을 명시합니다.
회사는 기업 투자자용 프레젠테이션도 업데이트했으며, 이는 회사 웹사이트에서 확인할 수 있고 Exhibit 99.2로 첨부되어 있습니다. 8-K는 프레젠테이션 역시 furnished로 제공되었으며 'filed'로 간주되지 않는다고 반복하고, 인터랙티브 데이터 파일의 Cover Page를 Exhibit 104로 포함한 부속 문서를 열거합니다.
ARS Pharmaceuticals, Inc. a annoncé ses résultats financiers pour le trimestre clos le 30 juin 2025 par un communiqué de presse joint à ce Form 8-K en tant que Exhibit 99.1. La société indique que le communiqué est furnished et expressément non 'filed' aux fins de la Exchange Act, et n'est donc pas incorporé par référence dans d'autres dépôts. Le dépôt confirme également qu'ARS est une emerging growth company et que ses actions ordinaires sont négociées sur le Nasdaq sous le symbole SPRY.
La société a également mis à jour sa présentation aux investisseurs, disponible sur son site web et jointe en tant que Exhibit 99.2. Le Form 8-K répète que la présentation est furnished et n'est pas réputée 'filed', et énumère les annexes, y compris la Cover Page du fichier de données interactives en tant qu'Exhibit 104.
ARS Pharmaceuticals, Inc. gab die Finanzergebnisse für das Quartal zum 30. Juni 2025 in einer Pressemitteilung bekannt, die diesem Form 8-K als Exhibit 99.1 beigefügt ist. Das Unternehmen erklärt, dass die Pressemitteilung furnished und ausdrücklich nicht 'filed' im Sinne des Exchange Act ist und daher nicht durch Verweis in andere Einreichungen aufgenommen wird. Die Einreichung bestätigt zudem, dass ARS eine emerging growth company ist und dass die Stammaktien an der Nasdaq unter dem Symbol SPRY gehandelt werden.
Das Unternehmen hat außerdem seine Investorenpräsentation aktualisiert, die auf der Unternehmenswebsite verfügbar ist und als Exhibit 99.2 beigefügt wurde. Das 8-K wiederholt, dass die Präsentation furnished und nicht als 'filed' anzusehen ist, und listet die Anlagen auf, darunter die Cover Page der Interactive Data File als Exhibit 104.
FAQ
What did ARS Pharmaceuticals (SPRY) disclose in this 8-K?
Are the press release and presentation in the 8-K "filed" with the SEC?
Where can I find the updated corporate presentation mentioned in the 8-K?
What exhibits were included with this Form 8-K for ARS Pharmaceuticals?
Is ARS Pharmaceuticals considered an emerging growth company in this filing?
